[Effects of long term oxygen therapy in patients with idiopathic pulmonary fibrosis. I. Effect on the course of the primary disease and on pulmonary circulation].
The study was performed in 18 patients (15 F and 3-M) aged 35-57 yers (mean 46 +/- 7) diagnosed as idiopathic lung fibrosis. Ten patients (group A) recived standard treatment (prednisone 10-15 mg/day) and supplementary home oxygen therapy (mean 16.4 h/day) for a period of 4 years. During exacerbations antibiotics, theophylline and expectorants were prescribed. Eight patients (group B) receiving the same treatment without home oxygen, served as controls. At study entry lung function test (TLC, VL, Dlco), blood gases, hematocrit, hemodynamic parameters of the pulmonary circulation and thermodilution cardiac output were measured in all patients. The measurements were repeated after 4 years of follow-up. At follow-up examination no differences in pulmonary function parameters were shown between the groups. Mean pulmonary artery pressure and pulmonary vascular resistance were significantly lower in patients receiving home oxygen therapy (group A) as compared with those treated pharmacologically only (group B). Best effects of oxygen therapy were observed in patient with lower pulmonary artery pressures at study entry.
Poloński
L
L
II Katedra i Klinika Kardiologii, Slaskiej Akademii Medycznej, Zabrze.
Krzywiecki
A
A
Polońska
A
A
Tendera
M
M
Cwiertka
P
P
Oklek
K
K
Wodniecki
J
J
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D001993:Bronchodilator Agents / Q000627:therapeutic use; D005100:Expectorants / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006701:Home Nursing; D006801:Humans; D008297:Male; D008875:Middle Aged; D010102:Oxygen Inhalation Therapy; D011241:Prednisone / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000502:physiology; D011652:Pulmonary Circulation / Q000502:physiology*; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D012129:Respiratory Function Tests; D013806:Theophylline / Q000627:therapeutic use; D014655:Vascular Resistance / Q000502:physiology
D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D005100:Expectorants; D013806:Theophylline; D011241:Prednisone